Sebastian

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

EDDC is excited to share that we will be collaborating with Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, to bring forward an innovative approach for early drug discovery and development. In this partnership, Partex will initially use its “Asset Exchange” technology platform to identify novel indications for EDDC’s portfolio assets. The parties […]

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development Read More »

First Made-in-Singapore Antibody-Drug Conjugate EBC-129 progresses to Phase 1B Dose Expansion

EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets cancer cells across a range of solid tumours. The Phase 1 trial for EBC-129 began with a dose escalation study in May 2023. The trial has entered into dose expansion as of 13 May 2024. With the initial safety and

First Made-in-Singapore Antibody-Drug Conjugate EBC-129 progresses to Phase 1B Dose Expansion Read More »

Integrated IP Strategy for Platform Technologies and their Products

Join us for a webinar organised in partnership with Mewburn Ellis, one of Europe’s top specialist IP firms that has made a name for itself working with numerous local biotechs over the last decade, including MIRXES, Enleofen Bio, Hummingbird Bioscience, and the recently launched VVB Bio. In this seminar, we cover:   Identifying Protection Opportunities

Integrated IP Strategy for Platform Technologies and their Products Read More »

ImmunoScape Partners with Singapore’s Experimental Drug Development Centre to Develop Novel T Cell Receptor-Based Therapeutics

EDDC is proud to share that we are embarking on a partnership with ImmunoScape to develop novel T cell receptor-based therapeutics!  Under the terms of the agreement, ImmunoScape will contribute their repertoire of highly potent tumor-specific TCR candidates to EDDC’s expertise in therapeutic protein design and antibody engineering, to jointly develop innovative off-the-shelf TCR-based bispecific

ImmunoScape Partners with Singapore’s Experimental Drug Development Centre to Develop Novel T Cell Receptor-Based Therapeutics Read More »

Exploring the Drug Discovery and Development Landscape with Boehringer Ingelheim

This event has concluded. Thank you for attending this event. Check out our Events page for more such events!   Come join us on 5 Dec 2023 as we plug in to learn more about Boehringer Ingelheim (BI)’s initiatives to support academic research, as well as their partnering, licensing and venture investment interests! Our guest

Exploring the Drug Discovery and Development Landscape with Boehringer Ingelheim Read More »

XtalPi and EDDC sign MoU, minting new collaboration to empower biomedical innovation with robotics and Large Language Models (LLM)

XtalPi and EDDC embarks on a new collaboration with the signing of this MoU. This agreement builds and expands from an ongoing collaboration that utilizes AI and automation to accelerate the drug discovery program for non-small cell lung cancer (NSCLC). With XtalPi’s automation resources and AI capabilities complimenting EDDC’s industry know-how in drug discovery and

XtalPi and EDDC sign MoU, minting new collaboration to empower biomedical innovation with robotics and Large Language Models (LLM) Read More »

EDDC Satellite Seminar – Preclinical in vivo Studies for Drug Discovery and Development

EDDC Satellite Seminar – Preclinical in vivo Studies for Drug Discovery and Development Well-designed preclinical in vivo studies are of pivotal importance in the drug development journey and contributes immensely towards a successful IND (Investigational New Drug) approval.   In this upcoming session of the EDDC Satellite Seminar series, Associate Director of EDDC’s Translational Sciences

EDDC Satellite Seminar – Preclinical in vivo Studies for Drug Discovery and Development Read More »

EARO Review (2020 – 2022) – A Review of EARO’s first 3 years

EARO turns 3 this year! To mark this occasion, we are excited to share the EARO Review (2020-2022)! EDDC launched EARO (the EDDC Academic Research Organisation) as a service initiative in mid-2020. The goal was to enable early-stage drug discovery in Singapore by creating multiple pathways for the local academic and biotech community to access

EARO Review (2020 – 2022) – A Review of EARO’s first 3 years Read More »